261 related articles for article (PubMed ID: 30187393)
41. Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care.
Kao SC; van Zandwijk N; Clarke S; Vardy J; Lumba S; Tognela A; Ng W
Asia Pac J Clin Oncol; 2015 Mar; 11(1):85-92. PubMed ID: 25382807
[TBL] [Abstract][Full Text] [Related]
42. Italian version of the M.D. Anderson Symptom Inventory--Head and Neck Module: linguistic validation.
Greco A; Orlandi E; Mirabile A; Takanen S; Fallai C; Iacovelli NA; Rimedio A; Russi E; Sala M; Monzani D; Rosenthal DI; Gunn GB; Steca P; Licitra L; Bossi P
Support Care Cancer; 2015 Dec; 23(12):3465-72. PubMed ID: 25791393
[TBL] [Abstract][Full Text] [Related]
43. The use of patient-reported outcome measures (PROMs) in the management of malignant pleural mesothelioma: a descriptive literature survey.
Ben Bouazza Y; Van Meerbeeck JP
Transl Lung Cancer Res; 2018 Oct; 7(5):507-515. PubMed ID: 30450288
[TBL] [Abstract][Full Text] [Related]
44. Physical function and health-related quality of life in patients undergoing surgical treatment for malignant pleural mesothelioma.
Tanaka T; Morishita S; Hashimoto M; Itani Y; Mabuchi S; Kodama N; Hasegawa S; Domen K
Support Care Cancer; 2017 Aug; 25(8):2569-2575. PubMed ID: 28293731
[TBL] [Abstract][Full Text] [Related]
45. Physical function and health-related quality of life in the convalescent phase in surgically treated patients with malignant pleural mesothelioma.
Tanaka T; Morishita S; Hashimoto M; Nakamichi T; Uchiyama Y; Hasegawa S; Domen K
Support Care Cancer; 2019 Nov; 27(11):4107-4113. PubMed ID: 30788627
[TBL] [Abstract][Full Text] [Related]
46. Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study.
Nagamatsu Y; Oze I; Aoe K; Hotta K; Kato K; Nakagawa J; Hara K; Kishimoto T; Fujimoto N
BMC Cancer; 2018 Mar; 18(1):350. PubMed ID: 29587685
[TBL] [Abstract][Full Text] [Related]
47. The psychometric properties of cancer multisymptom assessment instruments: a clinical review.
Aktas A; Walsh D; Kirkova J
Support Care Cancer; 2015 Jul; 23(7):2189-202. PubMed ID: 25894883
[TBL] [Abstract][Full Text] [Related]
48. Predictors of quality of life improvement after surgery for metastatic tumors of the spine: prospective cohort study.
Barzilai O; McLaughlin L; Amato MK; Reiner AS; Ogilvie SQ; Lis E; Yamada Y; Bilsky MH; Laufer I
Spine J; 2018 Jul; 18(7):1109-1115. PubMed ID: 29122701
[TBL] [Abstract][Full Text] [Related]
49. Single-item discrimination of quality-of-life-altering dysphagia among 714 long-term oropharyngeal cancer survivors: Comparison of patient-reported outcome measures of swallowing.
; Grant S; Kamal M; Mohamed ASR; Zaveri J; Barrow MP; Gunn GB; Lai SY; Lewin JS; Rosenthal DI; Wang XS; Fuller CD; Hutcheson KA
Cancer; 2019 May; 125(10):1654-1664. PubMed ID: 30633325
[TBL] [Abstract][Full Text] [Related]
50. Patient-reported outcome measures in surgical patients with upper gastrointestinal cancers: A qualitative interview study.
Cass SH; Williams LA; Rajaram R; Hirata Y; Rice D; Tzeng CD; Katz MHG; Badgwell BD; Wang XS; Ikoma N
J Surg Oncol; 2024 May; ():. PubMed ID: 38798277
[TBL] [Abstract][Full Text] [Related]
51. Symptom Burden and Unmet Needs in Malignant Pleural Mesothelioma: Exploratory Analyses From the RESPECT-Meso Study.
Hoon SN; Lawrie I; Qi C; Rahman N; Maskell N; Forbes K; Gerry S; Monterosso L; Chauhan A; Brims FJH
J Palliat Care; 2021 Apr; 36(2):113-120. PubMed ID: 32791881
[TBL] [Abstract][Full Text] [Related]
52. Linguistic Validation of the M. D. Anderson Symptom Inventory in Persian-Speaking Iranian Cancer Patients.
Saadatpour L; Hemati S; Habibi F; Behzadi E; Hashemi-Jazi MS; Kheirabadi G; Mirbagher L; Gholamrezaei A
J Pain Symptom Manage; 2015 Sep; 50(3):387-393.e1. PubMed ID: 25980966
[TBL] [Abstract][Full Text] [Related]
53. Symptoms in the general Norwegian adult population - prevalence and associated factors.
Krogstad H; Loge JH; Grotmol KS; Kaasa S; Kiserud CE; Salvesen Ø; Hjermstad MJ
BMC Public Health; 2020 Jun; 20(1):988. PubMed ID: 32576168
[TBL] [Abstract][Full Text] [Related]
54. Reproducibility of Malignant Pleural Mesothelioma Histopathologic Subtyping.
Brcic L; Vlacic G; Quehenberger F; Kern I
Arch Pathol Lab Med; 2018 Jun; 142(6):747-752. PubMed ID: 29509030
[TBL] [Abstract][Full Text] [Related]
55. Qualitative Development and Content Validity of the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument.
McCarrier KP; Atkinson TM; DeBusk KP; Liepa AM; Scanlon M; Coons SJ;
Clin Ther; 2016 Apr; 38(4):794-810. PubMed ID: 27041408
[TBL] [Abstract][Full Text] [Related]
56. Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory.
Gning I; Trask PC; Mendoza TR; Harle MT; Gutierrez KA; Kitaka SA; Sherman SI; Cleeland CS
Oncology; 2009; 76(1):59-68. PubMed ID: 19052478
[TBL] [Abstract][Full Text] [Related]
57. Validation of the Spanish version of the MD Anderson symptom inventory - heart failure (MDASI-HF-Spanish) module.
Fadol A; Buitrago J; Diaz MC; Shelton V; Harty C; Mendoza TR
Cardiooncology; 2019; 5():19. PubMed ID: 32154025
[TBL] [Abstract][Full Text] [Related]
58. Patient-reported outcomes of symptom burden in patients receiving surgical or nonsurgical treatment for low-intermediate risk oropharyngeal squamous cell carcinoma: A comparative analysis of a prospective registry.
Amit M; Hutcheson K; Zaveri J; Lewin J; Kupferman ME; Hessel AC; Goepfert RP; Brandon Gunn G; Garden AS; Ferraratto R; Dave Fuller C; Tam S; Gross ND
Oral Oncol; 2019 Apr; 91():13-20. PubMed ID: 30926057
[TBL] [Abstract][Full Text] [Related]
59. Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial.
Brims F; Gunatilake S; Lawrie I; Marshall L; Fogg C; Qi C; Creech L; Holtom N; Killick S; Yung B; Cooper D; Stadon L; Cook P; Fuller E; Walther J; Plunkett C; Bates A; Mackinlay C; Tandon A; Maskell NA; Forbes K; Rahman NM; Gerry S; Chauhan AJ;
Thorax; 2019 Apr; 74(4):354-361. PubMed ID: 30661019
[TBL] [Abstract][Full Text] [Related]
60. CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.
Cortes-Dericks L; Schmid RA
Respir Res; 2017 Apr; 18(1):58. PubMed ID: 28403901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
